GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (TSE:4503) » Definitions » Shiller PE Ratio

Astellas Pharma (TSE:4503) Shiller PE Ratio : 19.60 (As of Mar. 24, 2025)


View and export this data going back to 1949. Start your Free Trial

What is Astellas Pharma Shiller PE Ratio?

As of today (2025-03-24), Astellas Pharma's current share price is 円1494.00. Astellas Pharma's E10 for the quarter that ended in Dec. 2024 was 円76.21. Astellas Pharma's Shiller PE Ratio for today is 19.60.

The historical rank and industry rank for Astellas Pharma's Shiller PE Ratio or its related term are showing as below:

TSE:4503' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.35   Med: 23.2   Max: 40.34
Current: 19.26

During the past years, Astellas Pharma's highest Shiller PE Ratio was 40.34. The lowest was 18.35. And the median was 23.20.

TSE:4503's Shiller PE Ratio is ranked better than
64.72% of 462 companies
in the Drug Manufacturers industry
Industry Median: 24.055 vs TSE:4503: 19.26

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Astellas Pharma's adjusted earnings per share data for the three months ended in Dec. 2024 was 円-54.550. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is 円76.21 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Astellas Pharma Shiller PE Ratio Historical Data

The historical data trend for Astellas Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Shiller PE Ratio Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.99 21.53 22.98 21.66 20.38

Astellas Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.40 20.38 19.45 19.94 20.14

Competitive Comparison of Astellas Pharma's Shiller PE Ratio

For the Drug Manufacturers - General subindustry, Astellas Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Shiller PE Ratio falls into.



Astellas Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Astellas Pharma's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=1494.00/76.21
=19.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Astellas Pharma's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-54.55/110.7000*110.7000
=-54.550

Current CPI (Dec. 2024) = 110.7000.

Astellas Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 9.610 97.900 10.866
201506 20.350 98.400 22.894
201509 26.920 98.500 30.254
201512 28.630 98.100 32.307
201603 13.800 97.900 15.604
201606 31.310 98.100 35.331
201609 22.770 98.000 25.721
201612 30.200 98.400 33.975
201703 19.290 98.100 21.768
201706 20.540 98.500 23.084
201709 19.370 98.800 21.703
201712 29.970 99.400 33.377
201803 11.260 99.200 12.565
201806 27.650 99.200 30.855
201809 25.470 99.900 28.224
201812 45.600 99.700 50.631
201903 16.410 99.700 18.221
201906 31.000 99.800 34.386
201909 37.100 100.100 41.029
201912 32.780 100.500 36.107
202003 3.190 100.300 3.521
202006 27.120 99.900 30.052
202009 12.070 99.900 13.375
202012 32.330 99.300 36.042
202103 -6.630 99.900 -7.347
202106 16.550 99.500 18.413
202109 22.080 100.100 24.418
202112 32.840 100.100 36.318
202203 -4.430 101.100 -4.851
202206 13.590 101.800 14.778
202209 39.280 103.100 42.176
202212 26.550 104.100 28.233
202303 -25.310 104.400 -26.837
202306 18.420 105.200 19.383
202309 -0.810 106.200 -0.844
202312 8.060 106.800 8.354
202403 -18.550 107.200 -19.156
202406 20.940 108.200 21.424
202409 19.970 108.900 20.300
202412 -54.550 110.700 -54.550

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Astellas Pharma  (TSE:4503) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Astellas Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

No Headlines